A randomised double-blind placebo-controlled cancer prevention trial with an estimated duration of 5 years and with 52,000 subjects recruited from the general populations of the UK, Denmark, Sweden, Finland and the United States

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN64336220

Enrollment

52000

Registered

2001-07-01

Start date

1995-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple cancer sites Cancer Malignant neoplasm without specification of site

Interventions

Four treatment groups: 1. Placebo 2. 100 micrograms selenium/day 3. 200 micrograms selenium/day 4. 300 micrograms selenium/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All those aged between 60 and 74 years are eligible.

Exclusion criteria

Exclusion criteria: 1. Southwest Oncology Group (SWOG) performance status score of greater then 1 or equivalent 2. Active liver or kidney disease 3. Prior diagnosis of cancer 4. Diagnosed Human Immunodeficiency Virus (HIV) infection 5. Disminished mental capacity 6. Taking 50 micrograms/day or more of selenium supplements

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

Denmark, Finland, Sweden, United Kingdom, United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026